Cipla Limited (Cipla) a public limited company and its equity shares are listed on NSE (National Stock Exchange) and BSE (Bombay Stock Exchange); and its Global Depository Receipts (GDR) listed on Luxembourg Stock Exchange. It is engaged in the business of manufacturing and sale pharmaceutical products.

Cipla Biotec Limited (CBL) is engaged in the business of research and development and manufacture of pharmaceutical products including biopharmaceuticals and providing numerous services in contract research, contract manufacturing etc. CBL is a wholly-owned subsidiary of Cipla.

Cipla Health Limited (CHL) is engaged in the business of development, manufacture, and marketing of Nicotex and Nicogum, Cofsils, Unobiotics, MamaXpert, Prolyte and Ciphands and other brands. CHL is a wholly-owned subsidiary (WoS) of Cipla.

The Transaction:

Cipla-Demerger-Business-to-Subsidiaries-1

In simple terms, Cipla Limited demerged its US Business and Consumers Business into CBL and CHL, respectively.

Appointed Datefor the transaction is opening of business hours of April 1, 2021.

Rationale of the scheme:

Already a user? Sign in

Your email address will not be published. Required fields are marked *

*

1 Comments


Join the conversation

  • MD says:

    NA